FRAMINGHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Kevin Coop, and its Chief Financial Officer, Rick Booth, will present at the Raymond James 2025 Institutional Investors Conference.
The Definitive Healthcare presentation is scheduled for Tuesday, March 4, 2025, at 3:25 p.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the Definitive Healthcare investor relations website at https://ir.definitivehc.com/. A replay of the webcast will also be available for a limited time.
About Definitive Healthcare
At Definitive Healthcare, our mission is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS products and solutions create new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.
Investor Contact:
Brian Denyeau
ICR for Definitive Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
646-277-1251
Media Contact:
Bethany Swackhamer
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.19 |
| Daily Change: | 0.02 0.36 |
| Daily Volume: | 432,704 |
| Market Cap: | US$449.220M |
February 27, 2025 November 07, 2024 October 10, 2024 August 29, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
